Gilead’s Sponsored Link For Viread Can’t Prevent Trouble With FDA
This article was originally published in The Pink Sheet Daily
Agency cites firm for unapproved claim, not including any risk information, and not submitting link to FDA.
You may also be interested in...
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
Draft guidances say tweets about a product must balance benefit and risk information, and firms cannot be selective in correcting information on third-party sites.
FDA says keywords don’t need OPDP’s formal review, but that doesn’t mean they don’t have an opinion about how they’re used.